// App-Quantinova.ai

3958 : A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

Researchers

Presenter

  • David M Goldenberg

Principal Investigators

  • N/A

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Immunomedics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Chronic Myelogenous Leukemia

  • Multiple Myeloma

Biomarkers

  • Breakpoint Cluster Region

  • Apparent diffusion coefficient

Drug/Treatment

  • IMMU-114

  • SN38

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved